RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Friday or 4pm NR is betterIt means that on October 13 they already had one patient tested at 420 mg/m2, the one that had a grade 2 neutropenia. That was more than three months ago, and since then they are still at 420 mg/m2. So three months stuck at the same dose, or they went to 560 mg/m2, had DLT, and are now back at 420 mg/m2. The other possibility is that they know 420 mg/m2 will be the MTD, and they wait for scans on patients to be done, hopefully, with some good efficacy data.
mikeq113 wrote: Two excerpts from the last earnings call I'm referencing:
35:59 Then we're getting close to the MTD. That's the dose that we're expecting based on the animal model, we need two more patients to be able to define our MTD, but it doesn't mean that in terms of efficacy, that it wouldn’t show efficacy at lower doses. Then we're on track. We continue MTD. We should probably reach MTD towards, hopefully the end of this year and after that we’ll be able to initial our basket trial beginning of twenty twenty two.
40:49 In terms of the timing, we're right up. The cycles are given every three weeks, but to recruit the following patient, we need to have all of the safety data. We need to [indiscernible] data carefully. It would take probably four to five weeks between each patient and I must say that at the moment, we're right on the target and probably even higher to some extent to four twenty milligram and now we will decide once we have all of the information and safety, what will be the next dose for the following patients and if we need to enroll more patients at the following doses.